GRI Bio, Inc. (NASDAQ:GRI – Get Free Report) was the target of a large increase in short interest in September. As of September 30th, there was short interest totalling 169,100 shares, an increase of 17.7% from the September 15th total of 143,700 shares. Approximately 5.8% of the shares of the company are short sold. Based on an average trading volume of 973,600 shares, the short-interest ratio is presently 0.2 days.
GRI Bio Stock Up 25.4 %
Shares of GRI Bio stock traded up 0.09 on Wednesday, reaching 0.46. 15,603,801 shares of the company were exchanged, compared to its average volume of 462,904. GRI Bio has a 1-year low of 0.30 and a 1-year high of 142.87. The company’s 50-day moving average is 0.47 and its two-hundred day moving average is 2.70.
GRI Bio (NASDAQ:GRI – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported -4.92 earnings per share for the quarter.
Institutional Trading of GRI Bio
Analysts Set New Price Targets
Separately, Ascendiant Capital Markets began coverage on shares of GRI Bio in a research report on Tuesday, October 8th. They set a “buy” rating and a $12.00 price objective for the company.
GRI Bio Company Profile
GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
Featured Articles
- Five stocks we like better than GRI Bio
- What is a Low P/E Ratio and What Does it Tell Investors?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Quiet Period Expirations Explained
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Investing in Construction Stocks
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.